Validation of the newly FDA-approved Buhlmann fCal Turbo assay for measurement of fecal calprotectin in a pediatric population

OBJECTIVES: Inflammatory bowel disease (IBD) is an increasingly prevalent disorder marked by chronic intestinal inflammation. Fecal calprotectin has emerged as a useful biomarker for differential diagnostics and monitoring IBD activity. We validated the newly FDA-approved fCal Turbo fecal calprotect...

Descripción completa

Detalles Bibliográficos
Autores principales: Garnett, Emily, Pagaduan, Jayson, Rajapakshe, Deepthi, Tam, Estella, Kellermayer, Richard, Devaraj, Sridevi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585138/
https://www.ncbi.nlm.nih.gov/pubmed/33134465
http://dx.doi.org/10.1016/j.plabm.2020.e00178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585138/
https://www.ncbi.nlm.nih.gov/pubmed/33134465
http://dx.doi.org/10.1016/j.plabm.2020.e00178

Ejemplares similares